The Interleukin 1 Beta pipeline drugs market research report outlays comprehensive information on the Interleukin 1 Beta targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Interleukin 1 Beta pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Immunology, Dermatology, Oncology, and Musculoskeletal Disorders which include the indications Inflammation, Rheumatoid Arthritis, Epidermolysis Bullosa, Hidradenitis Suppurativa, Squamous Non-Small Cell Lung Cancer, Metastatic Melanoma, Osteoarthritis, and Gouty Arthritis (Gout). It also reviews key players involved in Interleukin 1 Beta targeted therapeutics development with respective active and dormant or discontinued products.
The Interleukin 1 Beta pipeline targets constitutes close to 29 molecules. Out of which, approximately 28 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 3, 6, 5, 1, 8, and 5 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Interleukin 1 Beta overview
Interleukin 1 beta (IL-1beta) is a cytokine protein that is encoded by the IL1B gene in humans. It is also known as leukocytic pyrogen, leukocytic endogenous mediator, mononuclear cell factor, and lymphocyte activating factor. IL-1beta is a key mediator of the inflammatory response. It is essential for the host response and resistance to pathogens, but it can also exacerbate damage during chronic disease and acute tissue injury.
For a complete picture of Interleukin 1 Beta’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
